Risk of cancer development in relation to oral contraception

European Journal of Contraception and Reproductive Health Care

Volumn 11, Issue 3, 2006, Pages 162-168

  Lech, Medard M ^a,c   Ostrowska, Lucyna ^b  

^a Fertility and Infertility Research Centre   (Poland)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^c Fertility and Sterility Research Center   (Poland)

Author keywords

Cancer risk; Combined oral contraceptives; Epidemiology; Steroids

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

BREAST CANCER; CANCER RISK; DRUG USE; ENDOMETRIUM CANCER; HUMAN; LIVER CANCER; MELANOMA; ORAL CONTRACEPTION; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CANCER;

BREAST NEOPLASMS; CONTRACEPTIVES, ORAL, COMBINED; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; NEOPLASMS; RISK ASSESSMENT;

EID: 33750322194     PISSN: 13625187     EISSN: 14730782     Source Type: Journal    
DOI: 10.1080/13625180600815706     Document Type: Review

References (39)

1. Hatcher RA, Trussel J, Stewart F, et al. Contraception Technology, 16th revised edition. New York: Irvington Publishers, 1994.
2. Szamatowicz M. Antykoncepcja hormonalna u progu XXI wieku. Wiad Poł Gin 2000;1:45-56.
3. Service RF. New role for the estrogen in cancer? Science 1998;279:1631-3.
4. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer from 54 epidemiological studies. Lancet 1996;347:1713-27.
5. Hankinson SE, Colditz GA, Manson JE, et al. A prospective study of oral contraceptive use and risk of breast cancer. Cancer Causes Control 1997;8:65-72.
6. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. New Engl J Med 2002;346:2025-32.
7. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 2001;358:1389-99.
8. Grabick DM, Harmann LC, Cerhan JR, et al. Risk of breast cancer with oral contraceptive use in women with a family cancer. J Am Med Assoc 2000;284:1791-8.
9. Heimdal K, Skovlund E, Moller P. Oral contraceptives and risk of familial breast cancer. Cancer Detect Prev 2002;26:23-7.
10. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. New Engl J Med 2002;346:2025-32.
11. Beral V, Hermon C, Kay C, et al. Mortality associated with oral contraceptive use: 25 year follow up cohort of 46 000 women from Royal College of General Practitioners' oral contraception study. Br Med J 1999;318:96-100.
12. Verheul HAM, Coellingh-Bennink HJT. Effects of estrogens and hormone replacement therapy on breast cancer risk and on efficacy of breast cancer therapies. Maturitas 2000;36:1-17.
13. Kenemans P, Van der Mooren J. The breast and post-menopausal hormone therapy: the risk in perspective. Gynaecol Forum 2004;9:15-7.
14. Speroff L. Spojrzenie z dystansu na raport WHI dotycza̧cy raka sutka. Gin po Dypl 2004;6:55-9.
15. Pujol P, This P, Norizunia M, et al. Are the hereditary forms of BRCA 1 and BRCA 2 breast cancer sensitive to estrogens? Bull Cancer 2004;91:583-91.
16. Narod SA, Dube MP, Klijn J, et al. Oral contraceptive use increased the risk of breast cancer in BRCA1, but not BRCA2, mutations carriers. J Natl Cancer Inst 2002;94:1173-9.
17. Milne RL, Knight JA, John EM, et al. Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 2005;14:350-6.
18. Polskie Towarzystwo Ginekologiczne. Rekomendacje dotycza̧ce ryzyka dziedzicznie uwarunkowanego zachorowania na raka gruczołu sutkowego i jajnika. Gin po Dypl 2004;6:53-4.
19. Scott A, Glasier A. Routine breast and pelvic examinations before prescription of hormonal contraception. IPPF Med Bull 2003;37:1-2.
20. Westhof CL. Breast cancer risk: perception versus reality. Contraception 1999:59(Suppl 1):25-8S.
21. Bucholc M, Łepecka-Klusek C, Pilewska A, Kanadys K. Ryzyko zachorowania na raka piersiwopinii kobiet. Gin Pol 2001;72:1460-4.
22. Smith J, Green J, Berrington de Gonzalez A, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003;361:1159-67.
23. Miller K, Blumenthal P, Blanchard K. Oral contraceptives and cervical cancer: critique of a recent review. Contraception 2004;69:347-51.
24. de Villiers EM. Relationship between steroid hormone contraceptives and HPV, cervical intraepithelial neoplasia and cervical carcinoma. Int J Cancer 2003;103:705-8.
25. Moreno V, Bosch FX, Munoz N, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 2002;359:1085-92.
26. Crosignani PG, Vegetti W, Bianchedi D. Hormonal contraception and ovarian pathology. Eur J Contracept Reprod Health Care 1997;2:207-11.
27. Ness RB, Grisso JA, Klapper J, et al. Oral contraceptives, other methods of contraception, and reduced risk for ovarian cancer. Epidemiology 2001;12:307-12.
28. Bosetti C, Negri E, Trichopoulos D, et al. Long-term effects of oral contraceptives on ovarian cancer risk. Int J Cancer 2002;102:262-5.
29. Narod SA, Risch H, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. New Engl J Med 1998;339:424-8.
30. Modan B, Hartge P, Hirsch-Yechezkel G, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. New Engl J Med 2001;345:235-40.
31. Greer JB, Modugno T, Glen O, et al. Short term oral contraceptives use and the risk of epithelial ovarian cancer. Am J Epidemiol 2005;162:66-72.
32. Schlesselmman JJ, Collins JA. The influence of steroids on gynecologic cancers. In Fraser IS, Jansen RPS, Lobo RA, Whitehead MI, eds. Estrogens and progestogens in clinical practice. London: Churchill Livingstone, 1999: 831-64.
33. Fernandez E, La Vecchia C, Balducci A, et al. Oral contraceptives and colorectal cancer risk: a meta-analysis. Br J Cancer 2001;81:722-7.
34. Hannaford P, Elliot A. Use of exogenous hormones by women and colorectal cancer: evidence from the Royal College of General Practitioners' Oral Contraception Study. Contraception 2005;71:95-8.
35. Tajada M, Nerin J, Ruiz MM, et al. Liver adenoma and focal nodular hyperplasia associated with oral contraceptives. Eur J Contracept Reprod Health Care 2001;6:227-30.
36. Heinemann LAJ, DoMinh T, Guggenmoos-Holzmann I, et al. Oral contraceptives and liver cancer. Contraception 1997;56:275-84.
37. Feskanich D, Hunter DJ, Willett WC, et al. Oral contraceptive use and risk of melanoma in premenopausal women. Br J Cancer 1999;81:918-23.
38. Pfahlberg A, Hassan K, Wille L, et al. Systematic review of case-control studies: Oral contraceptives show no effect on melanoma risk. Public Health Rev 1997;25:309-15.
39. Victory R, Souza CD, Diamond MP, et al. Reduced cancer risks in oral contraceptive users: Results from the Women's Health Initiative. Fertil Steril 2004;82(Suppl 2):S104-5.